“Failure is temporary but giving up is permanent”
Secret Diary Of Kiran Mazumdar – Part 2
Kripa Mahalingam - May 08, 2018
The Comeback Plan
Lupin is betting on its specialty drugs business to counter the pricing pressures in the US generics market
Khushboo Balani - October 03, 2017
Bold and Bountiful
Not content with the initial win in biosimiliars, Kiran Mazumdar-Shaw is pushing new frontiers in biologics
Kripa Mahalingam - July 11, 2017
Vivek Pandey
Private portfolio manager Vivek Pandey is backing Wockhardt thanks to its long ANDA pipeline
Vivek Pandey - December 10, 2015